Dr Sarah White[/caption]
Rory Johnston MPS[/caption]
There is often a perception that people are simply overweight due to overeating, said Mr Johnston, but there are myriad conditions and medicine classes that can cause patients to gain weight, including:
Aetiology and pathophysiology 
Initial symptoms are usually mild and may include1,2,8:
Delays in diagnosis may result from various factors.11 This may include patients not seeking immediate diagnosis, initial misdiagnosis, referral to non-neurological specialists and delayed referral to a neurologist.11 General practitioners will probably only encounter one patient with MND in their careers.1,11 Differential diagnoses may include a variety of other neurological conditions, including Kennedy’s disease, an inherited disorder which progresses very slowly, involves only lower motor neurones and exhibits similar symptoms to those of MND.1,2 
Why did you decide to become one of the very first pharmacist prescribers? 
References
- Lawrence A, Scott S, Saparelli F, et al. Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach. J Prim Health Care 2019;11(2):117–27.
- Goldfien R, Pressman A, Jacobson A, et al. A pharmacist-staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial. Perm J 2016;20(3):15–234.
- Goldfien RD, Ng MS, Yip G, et al. Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. BMJ Open 2014;4(1):e003627.
- Mikuls TR, Cheetham TC, Levy GD, et al. Adherence and outcomes with urate-lowering therapy: a site-randomized trial. Am J Med 2019;132(3):354–61.
- Pathmanathan K, Robinson PC, Hill CL, et al. The prevalence of gout and hyperuricaemia in Australia: an updated systematic review. Semin Arthritis Rheum 2021;51(1):121–8.
- Nguyen AD, Lind KE, Day RO, et al. A profile of health status and demographics of aged care facility residents with gout. Australas J Ageing 2020;39(1):e153–e61.
- Robinson PC, Taylor WJ, Dalbeth N. An observational study of gout prevalence and quality of care in a national Australian general practice population. J Rheumatol 2015;42(9):1702–7.
- Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 2024;6(8):E507–17.
- McDougall C, Hurd K, Barnabe C. Systematic review of rheumatic disease epidemiology in the indigenous populations of Canada, the United States, Australia, and New Zealand. Semin Arthritis Rheum 2017;46(5):675–86.
- Dalbeth N, Gosling AL, Gaffo A, et al. Lancet 2021;397(10287):1843–55.
- Borghi C, Agnoletti D, Cicero AFG, et al. Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk. Hypertension 2022;79(9):1927–36.
- Yokose C, McCormick N, Choi HK. The role of diet in hyperuricemia and gout. Curr Opin Rheumatol 2021;33(2):135–44.
- Uhlig T, Karoliussen LF, Sexton J, et al. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study. Clin Rheumatol 2022;41(12):3817–23.
- Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 2020;79(1):31–8.
- Therapeutic Guidelines. Gout [Internet] 2023. At: www.tg.org.au.
- Zhang J, Sun W, Gao F, et al. Changes of serum uric acid level during acute gout flare and related factors. Front Endocrinol (Lausanne) 2023;14:1077059.
- Macmullan P, McCarthy G. Treatment and management of pseudogout: insights for the clinician. Ther Adv Musculoskelet Dis 2012;4(2):121–31.
- Robinson PC, Stamp LK. The management of gout: much has changed. Aust Fam Physician 2016;45:299–302.
- Hill EM, Sky K, Sit M, et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol 2015;21(3):120–5.
- Lee YH, Song GG. Efficacy of initiating urate-lowering therapy during an acute gout episode: a meta-analysis. Z Rheumatol 2023;82(9):763–9.
- Taylor TH, Mecchella JN, Larson RJ, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012;125(11):1126–34.e7.
- NICE Evidence Reviews Collection. Evidence reviews for timing of urate-lowering therapy in relation to a flare in people with gout: Gout: diagnosis and management: Evidence review F. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2022.; 2022.
- Stamp LK, Dalbeth N. What is allopurinol failure and what should we do about it? J Rheumatol 2024;51(6):556–62.
- Nguyen AD, Lind KE, Day RO, et al. Measuring quality of gout management in residential aged care facilities. Rheumatol Adv Pract 2022;6(3):rkac091.
- Terrill M, Riordan J. A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia. Int J Rheum Dis 2017;20(8):990–5.
- Terrill M, Riordan J. A survey on the beliefs and knowledge of gout management in new medical graduates – New South Wales, Australia. Int J Rheum Dis 2018;21(2):517–22.
- Coleshill MJ, Day RO, Tam K, et al. Persistence with urate-lowering therapy in Australia: a longitudinal analysis of allopurinol prescriptions. Br J Clin Pharmacol 2022;88(11):4894–901.
- Spragg JCJ, Michael TJF, Aslani P, et al. Optimizing adherence to allopurinol for gout: patients’ perspectives. Br J Clin Pharmacol 2023;89(7):1978–91.
- Rogenmoser S, Arnold M. Chronic gout: barriers to effective management. Australian J Gen Pract. 2018;47:351–6.
- Arthritis Australia. Gout and diet fact sheet. 2024. At: https://arthritisaustralia.com.au/wordpress/wp-content/uploads/2024/09/Gout_and_Diet_FactSheet_v4.pdf
- Ofanoa S, Ofanoa M, Tu’akoi S, et al. Interventions designed to improve uptake of allopurinol for gout treatment in Aotearoa New Zealand: a scoping review. J Prim Health Care 2023;15(1):48–58.
